ArticleInternational journal of general medicine2024
Identification of Biomarkers Associated with Oxidative Stress in Aortic Dissection Based on Bulk Transcriptome Analyses.
Article in International journal of general medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study is to investigate the underlying molecular mechanism of oxidative stress (OS) involved in aortic dissection (AD). Methods: Datasets of AD and OS-related genes were obtained from the Gene Expression Omnibus (GEO) and the GeneCards database, respectively. Differential expression analysis and weighted gene correlation network analysis (WGCNA) were employed to screen genes. After enrichment analysis, a protein-protein interaction (PPI) network was constructed, and machine learning algorithms were used to determine signature genes. Comprehensive bioinformatics analyses on the signature genes were executed, and a clinical prediction model was established and evaluated. External datasets, in vitro experiment, and Mendelian randomization (MR) analysis were applied to validation. Results: We identified CCL2, ITGB4, MYC, SOCS3, SPP1 and TEK as OS-related signature genes in AD. The area under the ROC curve of all the signature genes was greater than 0.75. The clinical prediction model based on the signature genes showed satisfactory diagnostic efficacy in both training and validation cohorts. In validation cohort and in vitro experiment, CCL2, MYC, SPP1 and TEK were further validated. However, the MR results showed no causal association between the expression of the signature genes and AD. Conclusion: This study demonstrated that OS participates in and affects the progression of AD. Six biomarkers associated with OS could be perceived as crucial targets for the diagnosis and treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.